The Medicines Patent Pool has signed agreements with nine patent holders for thirteen HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 23 generic manufacturers and product developers have now signed MPP sublicensing agreements.

Overview of all licensing and sublicensing agreements

The below table provides an overview of manufacturer filing timelines per combination, countrywide filing status and plans for registration. Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 19 million patient years of HIV and hepatitis C products, saving international procurers USD631 million (Jan. 2012-June 2018).

Last update of the table: December 2018

This website uses cookies to ensure you get the best experience on our website. Learn More